Paris-based biotech startup Spotlight Medical, which develops personalized and effective care for cancer patients, has secured €6.2 million to improve cancer treatment with AI-powered prognosis tests. The investment was led by Kurma Partners and Heal Capital.
- Founded in 2024 by Sylvain Berlemont and backed by the cancer centers Institut Curie and Gustave Roussé, Spotlight Medical develops advanced AI-based clinical tests for cancer patients, launching the first definitive AI-driven solution in cancer care. By enhancing precision and treatment effectiveness, Spotlight Medical prioritizes personalized care, poised to revolutionize cancer diagnostics and therapy.
Deatils of the deal
- The fresh capital came from Kurma Partners, a Paris-based venture capital firm managing €470 million in assets. Specializing in healthcare startups, Kurma Partners has made 131 investments across 53 startups to date, with successful exits including Cardiologs, Asarina Pharma, and Corlieve Therapeutics.
“We were impressed by the quality of the team and by their unique technology, quite different from what we usually see in the field of precision oncology,” Partner at Kurma Partners, Benjamin Belot, stated.
- The investment also saw participation from Heal Capital, a Berlin-based venture capital company that funds technology-enabled healthcare founders from early to growth stages.
- The fresh funding will enable Spotlight Medical to launch its first prognosis test in the clinic, marking a significant milestone in the commercialization of AI-based solutions for cancer treatment.
“This investment will accelerate our mission to harness the power of AI in analyzing patient data, providing physicians with the insights they need to make more informed treatment decisions,” CEO of Spotlight Medical, Sylvain Berlemont, commented.
